Cantor Fitzgerald Target 9$ CDN Cheers!!!https://m.thefly.com/new-landing/3674665
Cantor Fitzgerald analyst Louise Chen initiated coverage of Oncolytics with an Overweight rating and C$9 price target. The potential for Oncolytics' clinical candidate, pelareorep, to boost the effectiveness of chemotherapy and a range of immunotherapies, with an immediate focus on checkpoint inhibitors, across multiple cancer indications is underappreciated, the analyst tells investors in a research note. The firm thinks pipeline advancements should drive earnings-estimate revisions and the stock higher.
Cantor Fitzgerald analyst Louise Chen initiated coverage of Oncolytics with an Overweight rating and C$9 price target. The potential for Oncolytics' clinical candidate, pelareorep, to boost the effectiveness of chemotherapy and a range of immunotherapies, with an immediate focus on checkpoint inhibitors, across multiple cancer indications is underappreciated, the analyst tells investors in a research note. The firm thinks pipeline advancements should drive earnings-estimate revisions and the stock higher.